View Older Stories View More Recent Stories

Aug 4, 2021 07:30AM Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
Jul 22, 2021 07:30AM Zai Lab to Announce Second Quarter 2021 Financial Results
Jun 16, 2021 07:33AM Zai Lab (ZLAB) and MacroGenics (MGNX) Enter Pact to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:30AM Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 1, 2021 07:36AM Mirati Therapeutics (MRTX), Zai Lab (ZLAB) Enter Into Collaboration to Develop and Commercialize Adagrasib in Greater China
Jun 1, 2021 07:30AM Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
Jun 1, 2021 07:30AM Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
May 28, 2021 07:30AM Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 28, 2021 07:30AM Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 25, 2021 07:30AM Zai Lab Announces Upcoming Presentations in June Investor Conferences
May 24, 2021 09:22AM Zai Lab (ZLAB) Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
May 24, 2021 09:21AM Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
May 10, 2021 07:32AM Zai Lab Announces First Quarter 2021 Financial Results
Apr 26, 2021 07:30AM Zai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021
Apr 13, 2021 07:38AM Zai Lab (ZLAB) Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer, DMC Says Trial Should Continue
Apr 13, 2021 07:37AM Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Mar 31, 2021 04:57AM China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Mar 1, 2021 07:00AM Zai Lab Announces Financial Results for Second-half and Full-year 2020
Feb 18, 2021 07:30AM Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
Jan 28, 2021 07:30AM Zai Lab Announces Upcoming Presentations in February Investor Conferences
Jan 11, 2021 06:45AM Turning Point and Zai Lab Broaden Collaboration
Jan 11, 2021 04:30AM Turning Point and Zai Lab Broaden Collaboration
Jan 6, 2021 04:01PM argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Dec 30, 2020 07:30AM Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
Dec 28, 2020 07:00PM Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
Dec 28, 2020 07:31AM Zai Lab Limited (ZLAB), Cullinan Oncology Report Strategic Collaboration and License Agreement for CLN-081 in Greater China
Dec 28, 2020 07:30AM Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Dec 16, 2020 08:15PM Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Dec 1, 2020 07:30AM Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
Nov 10, 2020 07:00PM Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-
Oct 29, 2020 07:30AM Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer
Oct 28, 2020 07:30AM Zai Lab Announces Upcoming Presentations in November Investor Conferences
Oct 9, 2020 08:48AM Zai Lab Announces Full Exercise of the Over-allotment Option
Oct 6, 2020 07:33AM Zai Lab Limited (ZLAB) Reports First Patient Dosed in Greater China in Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
Oct 6, 2020 07:30AM Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
Oct 5, 2020 07:32AM Zai Lab Limited (ZLAB) Reports First Patient Dosed in China in Global Ph. 3 Study of Retifanlimab in Patients with NSCLC
Oct 5, 2020 07:30AM Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC
Sep 28, 2020 07:30AM Zai Lab Announces Closing of Hong Kong Secondary Listing
Sep 28, 2020 07:30AM Zai Lab Announces Closing of Hong Kong Secondary Listing
Sep 22, 2020 07:53AM Zai Lab (ZLAB) Announces Pricing of Hong Kong Secondary Listing
Sep 22, 2020 07:53AM Zai Lab Announces Pricing of Hong Kong Secondary Listing
Sep 22, 2020 07:53AM Zai Lab Announces Pricing of Hong Kong Secondary Listing
Sep 19, 2020 07:30AM Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in C
Sep 19, 2020 07:30AM Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in C
Sep 16, 2020 07:15AM Zai Lab Limited (ZLAB) Launches Hong Kong Secondary Listing
Sep 16, 2020 07:15AM Zai Lab Launches Hong Kong Secondary Listing
Sep 10, 2020 07:32AM Zai Lab Limited (ZLAB) Reports NMPA Approval of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
Sep 10, 2020 07:30AM Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
Sep 10, 2020 07:30AM Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
Sep 3, 2020 07:30AM Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020
View More Recent Stories View Older Stories